ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy. (Q37808216)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

16 January 2020

title

ASA404: a tumor vascular-disrupting agent with broad potential for cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

16 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Bruce C Baguley

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

1 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

16 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

16 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

1537-1543

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

Disrupting tumour blood vessels

16 January 2020

cites work

1 reference

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

21 January 2018

1 reference

Flavone acetic acid--preclinical and clinical activity

21 January 2018

1 reference

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo

21 January 2018

1 reference

Antivascular therapy of cancer: DMXAA.

21 January 2018

1 reference

Lipopolysaccharide Induces Disseminated Endothelial Apoptosis Requiring Ceramide Generation

21 January 2018

1 reference

Role of ceramide in lipopolysaccharide (LPS)-induced signaling. LPS increases ceramide rather than acting as a structural homolog

21 January 2018

1 reference

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

21 January 2018

1 reference

Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability

21 January 2018

1 reference

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent

21 January 2018

1 reference

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

21 January 2018

1 reference

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

21 January 2018

1 reference

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

21 January 2018

1 reference

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.10.122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21062153 AND SRC:MED&resulttype=core&format=json

16 January 2020

1 reference